Andelyn Biosciences
Andelyn Biosciences is a Columbus, Ohio-based cell and gene therapy CDMO providing AAV and lentiviral viral vector manufacturing services from preclinical through commercial stages, serving biotech, pharma, academic, and nonprofit clients developing therapies for rare genetic diseases using its proprietary Curator platforms.
- Company typePrivate
- Founded2003
- HeadquartersColumbus, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Andelyn Biosciences does
Andelyn Biosciences is a privately-held contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with operations centered on viral vector manufacturing in Columbus, Ohio. Originating from gene therapy development and manufacturing operations at Nationwide Children's Hospital, the company operates three specialized facilities totaling more than 225,000 square feet, anchored by the 180,000 sq ft Andelyn Corporate Center (ACC) with 16 modular cGMP manufacturing suites. Its core technology stack consists of the AAV Curator® Platform, which has supported over 100 AAV programs and uses an Optimization-By-Design™ methodology with a clonal HEK293 suspension cell line supporting processes up to 2,000 liters, and the newly launched LVV Curator® Platform extending the same methodology to lentiviral vector manufacturing. Capabilities span plasmid manufacturing, process development, analytical development, quality control, technology transfer, and fill-finish, underpinned by a registered DIGITAL CDMO® digital platform.
The company generates revenue through project-based, multi-year CDMO contracts with biotech, pharmaceutical, academic, government, and nonprofit clients developing therapies primarily for rare and ultra-rare genetic diseases. Service engagements range from early-stage process development and IND-enabling studies through late-stage PPQ manufacturing and BLA-supporting activities, with the company reporting 85+ INDs approved globally and 500+ cGMP clinical batches produced. A secondary revenue stream comes from sublicensing proprietary capsid technologies—including MyoAAV plasmids and Stanton Lab CNS capsids from the Broad Institute, plus AAV-SLB101 from Solid Biosciences—to clients for internal research. Go-to-market is B2B enterprise sales led by a Chief Commercial Officer, supported by ASGCT conference presence, scientific content marketing, and direct business development outreach, with strategic partnerships (e.g., ENCell for US-APAC) extending geographic reach to over 20 countries.
Andelyn Biosciences firmographics
Firmographics- Name
- Andelyn Biosciences
- Legal name
- Andelyn Biosciences, Inc.
- Website
- https://andelynbio.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Andelyn Biosciences is a Columbus, Ohio-based cell and gene therapy CDMO providing AAV and lentiviral viral vector manufacturing services from preclinical through commercial stages, serving biotech, pharma, academic, and nonprofit clients developing therapies for rare genetic diseases using its proprietary Curator platforms.
- Ownership category
- akta.pro rank
Andelyn Biosciences industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Andelyn Biosciences is headquartered
LocationHeadquarters
- HQ city
- Columbus
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
Andelyn Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Manufacturing Services: Andelyn Biosciences generates revenue as a CDMO by providing fee-for-service manufacturing of viral vectors (AAV and lentiviral vectors) for cell and gene therapy companies. Services span from plasmid manufacturing through process development, analytical development, cGMP clinical and commercial manufacturing. Revenue is project-based, typically multi-year contracts with milestones.
- Platform Licensing: Through licensing agreements, Andelyn sublicenses proprietary capsid technologies (e.g., MyoAAV, Stanton Lab CNS capsids from Broad Institute, AAV-SLB101 from Solid Biosciences) to clients for internal research purposes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based pricing for CDMO services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Andelyn Biosciences product offering
Product offeringCore offering
Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that manufactures adeno-associated virus (AAV) and lentiviral viral vectors for biotech and pharmaceutical clients from preclinical through commercial stages. Its proprietary AAV Curator® and LVV Curator® Platforms, supported by integrated plasmid manufacturing, process development, analytical/QC laboratory services, and technology transfer, enable end-to-end contract manufacturing of gene therapies for rare and ultra-rare diseases.
Product overview
Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) offering a unified platform-plus-services architecture. The core products include the AAV Curator® Platform (supporting over 100 AAV programs) and the LVV Curator® Platform (lentiviral vector manufacturing). These manufacturing platforms are complemented by integrated services including Viral Vector Manufacturing, Plasmid Manufacturing, Process Development, Laboratory Services (Analytical Development and Quality Control), and Technology Transfer. The DIGITAL CDMO® Platform provides digital infrastructure support. The company operates three Columbus, Ohio facilities offering cGMP manufacturing for suspension processes up to 2,000 liters and adherent processes.
Differentiator
Problem solved
Functional benefit
Brands
- LVV Curator Platform: Standardized lentiviral vector manufacturing platform designed to address the challenge of transitioning cell and gene therapy programs from research-grade processes to GMP production.
- AAV Curator Platform
- DIGITAL CDMO Platform
Products and services
- AAV Curator® Platform Configurable, data-driven adeno-associated virus (AAV) gene therapy manufacturing platform that has supported over 100 AAV programs using Optimization-By-Design™ methodology. Supports both adherent and suspension processes up to 2,000 liters with a clonal HEK293 suspension cell line and is intended for biotech and pharma clients developing AAV gene therapies.
- LVV Curator® Platform Standardized lentiviral vector (LVV) manufacturing platform built on the Curator® methodology that addresses the transition of cell therapy programs from research-grade processes to GMP manufacturing, using a HEK293 cell line with clinical and regulatory experience. Targeted at cell therapy developers needing GMP-grade LVV for gene modification.
- Viral Vector Manufacturing Full-service cGMP viral vector manufacturing for AAV and lentiviral vectors, including suspension processes up to 2,000 liters and adherent processes, serving biotech and pharma clients from clinical through commercial-scale production.
- Plasmid Manufacturing cGMP plasmid manufacturing services for viral vector production, supporting gene therapy development from preclinical through commercial stages, including FDA Drug Master File support.
- Process Development Data-driven, analytical-based process development services that optimize manufacturing workflows for viral vector production, including upstream, downstream, and scale-up activities.
- Laboratory Services Comprehensive laboratory services for viral vector programs, encompassing analytical development (safety, purity, potency, yield testing) and quality control release and stability testing, supporting clients through production, purification, release, and stability.
- Technology Transfer Technology transfer service for moving established client manufacturing processes into Andelyn's cGMP facilities, enabling continuity of supply across sites and stages.
- DIGITAL CDMO® Platform Advanced digital model and platform supporting Andelyn's CDMO services, providing data-driven infrastructure for the gene therapy development and manufacturing workflow, including program visibility under the OneTeam™ collaboration model.
Quantifiable outcome
- 85+ INDs Approved globally
- +4 more outcomes
Companies that use Andelyn Biosciences
Customer profileNamed customers14 records
Segments3 records
Ideal customer profiles4 records
Andelyn Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Andelyn Biosciences partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and minor.
- ENCell Co., Ltd.coreStrategic manufacturing partnership establishing a 'dual hemisphere' workflow between US and Asia-Pacific regions. Combines GMP facilities, technical expertise, and regional networks to reduce regulatory and logistical complexities of international expansion. Enables in-country manufacturing for local clinical trials and patient populations.
- Evolyra TherapeuticscoreClinical manufacturing partnership for AAV gene therapies targeting Limb-Girdle Muscular Dystrophies types 2C and 2D (LGMDR3 and LGMDR5). Andelyn applies its AAV Curator Platform to support IND-enabling studies and GMP manufacturing for Phase I/II clinical trials.
- Drake Rayden FoundationcorePartnership to manufacture clinical-grade AAV for gene therapy targeting Nonketotic Hyperglycinemia (NKH), a rare inherited metabolic genetic disorder. Collaboration includes scientists from Dr. Steven Gray's laboratory at UT Southwestern.
- Jaguar Gene TherapycoreLate-stage PPQ (Process Performance Qualification) manufacturing partnership for JAG201, an investigational gene therapy targeting Phelan-McDermid syndrome (PMS) and SHANK3 haploinsufficiency.
- Solid BiosciencescoreNon-exclusive worldwide licensing agreement for proprietary next-generation capsid AAV-SLB101, which has demonstrated positive safety and efficacy signals in clinical and preclinical studies. Supports development of gene therapies for muscle and cardiac targets.
- Tern TherapeuticscorePartnership for late-stage PPQ manufacturing of AAV gene therapy for CLN2 Batten Disease treatment.
- Amplo BiotechnologycorePartnership for scalable manufacturing of clinical-grade AAV material for neuromuscular junction (NMJ) diseases using Andelyn's suspension AAV Curator platform.
- Nationwide Children's HospitalcoreManufactured viral vector with AAV Curator Platform for Nationwide Children's Hospital's Cellular Therapy and Cancer Immunology Program for Universal-Donor CAR-NK cell therapy clinical trial for AML.
- Broad Institute of MIT and Harvard (Stanton Lab)coreExpanded license agreement to include Stanton Lab CNS capsids that increase brain transduction and reduce peripheral organ tropism. Supports gene therapy manufacturing for nervous system disorders with up to 13x more potent neuroretina transduction.
- Hubble TherapeuticscoreSelected to manufacture clinical-grade AAV for Leber Congenital Amaurosis 16 (LCA16) treatment using suspension AAV Curator Platform. Generating GMP-grade plasmids and vectors.
- Broad Institute of MIT and HarvardcoreLicense Agreement for MyoAAV plasmids that produce AAVs 10x more efficient in reaching muscle tissue while de-targeting liver. Includes R&D services, screening, scale-up and preclinical development for IND-enabling studies. Permits sublicensing to clients.
- California Institute for Regenerative Medicine (CIRM)coreManufacturing partner for CIRM Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC). Manufacturing AAV therapies for rare diseases including Congenital Hereditary Endothelial Dystrophy - Type 1.
- Grace Science, LLCcoreTechnology transfer and Phase I/II/III manufacturing partnership for GS-100, a suspension process AAV NGLY1 gene therapy for NGLY1 Deficiency treatment.
- Armatus BiocorePartnership for suspension-based AAV gene therapy manufacturing for Charcot-Marie-Tooth Type 1A (CMT1A). Leverages Andelyn's AAV production expertise and proprietary suspension platform.
- UltragenyxcoreLate-stage PPQ manufacturing of UX111 gene therapy for Sanfilippo Syndrome (MPS IIIA). Andelyn successfully manufactured GMP supply for patient dosing and performs PPQ batches necessary for regulatory filings.
- Battelle and AmplifyBiocoreNINDS task order team for manufacturing gene therapy for Aspartylglucosaminuria (AGU). Andelyn manufactures plasmids and AAV vector; AmplifyBio performs IND-enabling GLP preclinical studies; Battelle provides assay support.
- The Ohio State UniversitycoreCollaboration with Ohio State University's Gene Therapy Institute for preclinical and GMP manufacturing of novel gene therapies for neurological disorders including Parkinson's, ALS, and Huntington's disease.
- Purespring TherapeuticscoreManufacturing partnership for gene therapies targeting chronic kidney diseases. Purespring leverages Andelyn's AAV production experience and suspension platform for preclinical and clinical GMP manufacturing.
- Columbus Innovation DistrictminorPart of the $1.1 billion Columbus Innovation District in Ohio, a collaborative healthcare and life sciences ecosystem including hospital systems, research institutions, and life sciences companies.
Scale indicators10 records
Recent moves2 records
Expansion highlights6 records
Andelyn Biosciences competitors and assessment
Company assessmentDirect peers
- Forge Biologics: Gene therapy CDMO specializing in AAV manufacturing with cGMP production capabilities. Direct competitor serving similar biotech and pharma clients in viral vector manufacturing for gene therapy programs.
- Yposkesi (Catalent): Cell and gene therapy CDMO acquired by Catalent, focused on AAV and lentiviral vector manufacturing for rare diseases. Highly comparable service offering and customer base to Andelyn.
- Vibalogics: Viral vector CDMO specializing in late-stage clinical and commercial manufacturing of oncolytic viruses, gene therapy vectors, and viral vaccines. Direct competitor for viral vector manufacturing services.
- Biovian: European CDMO offering AAV and other viral vector manufacturing for gene therapy clients. Comparable service portfolio targeting similar biotech customer segments.
- Cobra Biologics (Charles River Laboratories): Viral vector and plasmid DNA CDMO now part of Charles River Laboratories, providing gene therapy and viral vaccine manufacturing services. Direct competitor in viral vector CDMO space.
Broad incumbents
- Catalent: Global CDMO with substantial cell and gene therapy manufacturing capabilities, including viral vector production through its Paragon and acquired Yposkesi operations. Larger, broader portfolio but directly competes for gene therapy CDMO contracts.
- Lonza: One of the largest global CDMOs with established cell and gene therapy services including viral vector and cell therapy manufacturing. Competes for gene therapy CDMO engagements across all stages.
- AGC Biologics: Global CDMO with cell and gene therapy manufacturing capabilities including viral vector production. Broader portfolio but competes directly in gene therapy CDMO engagements.
Emerging players
- REGENXBIO: Clinical-stage biotechnology company developing AAV gene therapies with proprietary NAV technology platform. Notable as both a potential Andelyn client and as a competitor offering licensed capsid technology, similar to Andelyn's Broad Institute licensing model.
- Solid Biosciences: Gene therapy developer for Duchenne muscular dystrophy and other neuromuscular diseases with proprietary capsid technology (AAV-SLB101). Andelyn licenses this technology inbound, illustrating the bidirectional client/licensor relationship in gene therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
Andelyn Biosciences social profiles
Digital presenceAndelyn Biosciences compliance and trust
Trust signalCompliance1 record
Andelyn Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Andelyn Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Andelyn Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Andelyn Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Andelyn Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Andelyn Biosciences
What does Andelyn Biosciences do?
Andelyn Biosciences is a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that manufactures adeno-associated virus (AAV) and lentiviral viral vectors for biotech and pharmaceutical clients from preclinical through commercial stages. Its proprietary AAV Curator® and LVV Curator® Platforms, supported by integrated plasmid manufacturing, process development, analytical/QC laboratory services, and technology transfer, enable end-to-end contract manufacturing of gene therapies for rare and ultra-rare diseases.
Is Andelyn Biosciences a public or private company?
Andelyn Biosciences is a private company. It is classified as unknown and is currently operating.
When was Andelyn Biosciences founded?
Andelyn Biosciences was founded in 2003. It employs 251 to 500 people.
Where is Andelyn Biosciences based?
Andelyn Biosciences is headquartered in Columbus, United States, in the North America region.
How does Andelyn Biosciences make money?
Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are platform Licensing.
Who are Andelyn Biosciences's main competitors?
Direct peers on record are Forge Biologics, Yposkesi (Catalent), Vibalogics, Biovian and Cobra Biologics (Charles River Laboratories). Broad incumbents are Catalent, Lonza and AGC Biologics. Emerging players are REGENXBIO and Solid Biosciences.
Does Andelyn Biosciences have an API?
No public API is recorded for Andelyn Biosciences.
What industry is Andelyn Biosciences in?
Andelyn Biosciences's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 8731.